Catalyst Pharmaceuticals Inc. (CPRX) stock surged to a 12-year high of $5.59 on Wednesday. Investors were positive about the prospect of Firdapse
Categories
Health Care
Earnings: Affimed cuts down losses in 2018
Affimed N.V. (AFMD), a clinical stage biopharmaceutical company that focuses on oncology drugs, Wednesday reported net losses that narrowed in 2018, helped
Fennec Pharma stock plunges to all-time low
Fennec Pharmaceuticals Inc. (FENC) stock plunged to an all-time low of $4.69 on Tuesday. Investors were concerned about the future of the
Aldeyra Therapeutics stock resumes trading, surges about 60% on positive trial results
After getting halted in Nasdaq for sometime, shares of Aldeyra Therapeutics (ALDX) resumed trading and climbed up about 60% during the pre-market
Onconova Therapeutics cuts down losses in 2018
Onconova Therapeutics (ONTX), a Phase 3 biopharmaceutical company that focuses on developing cancer drugs, Tuesday posted a narrowed loss in fiscal 2018
Earnings Preview: Aeterna Zentaris reporting Q4 results on Mar 26
Aeterna Zentaris (AEZS) is scheduled to report its fourth-quarter financial results on March 26, Tuesday, after the regular trading hours. The specialty
Canopy Growth accelerates US expansion plans with AgriNextUSA acquisition
The world’s largest cannabis company by market cap, Canopy Growth Corporation (CGC), on Thursday said it was acquiring US-based hemp company AgriNextUSA,
What is NASH and which biotech firms are vying for the first-mover status
NASH, or Nonalcoholic steatohepatitis, is undeniably a golden goose in the pharma space. The biggest corporate attraction towards this liver disorder is
Aurinia’s loss widened to $14.6 million in Q4 2018
Aurinia Pharmaceuticals (NASDAQ: AUPH/TSX: AUP) reported its fourth quarter and full-year 2018 results after the bell today. The company reported a loss
Catalyst Pharma loss widens in Q4 due to Firdapse launch
Catalyst Pharmaceuticals (Nasdaq: CPRX) reported a loss of $0.14 per share compared to $0.12 loss expected by the street. The increase in
Dermira stock doubles and hits new 52-week high on positive eczema trial results
Dermira Inc. (DERM) announced positive results from Phase 2b study for treating patients with atopic dermatitis, a condition which causes redness, dryness
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of
NASH drug developer Genfit plans $132-million US IPO, to list on Nasdaq
France-based biopharmaceutical firm Genfit (EPA: GNFT) has launched a global offering of its American Depository Shares and ordinary shares to raise around
Novavax misses Q4 estimates, shares slip
NVAX Earnings Transcripts NVAX Earnings Calendar Clinical-stage vaccine company Novavax (NVAX) reported a loss of 13 per share in the fourth
Earnings Preview: Aurinia’s Q4 results pivot on AURORA trial updates
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH/TSX: AUP) rose 13% on February 25 when the US patent office extended the patent protection for
Earnings preview Q4: Amyris likely to benefit from the new cannabinoid deal
Renewables product company Amyris (AMRS) is set to report its fourth quarter and full-year 2018 results on Monday, March 18 after the
Latest FDA approval sends Arcadia Biosciences 23% higher
Shares of Arcadia Biosciences (RKDA) popped 23% during pre-market trading on Friday, after it received approval from the US Food And Drug
Tilray (TLRY) Q4 earnings preview: All you need to know
Tilray (TLRY), which has been trailing other cannabis stocks since the start of this year, will be put under the scanner as
Viking Therapeutics Q4 loss widens on higher expenses but beats estimates
Viking Therapeutics (VKTX) Wednesday posted a wider net loss for the fourth quarter of 2018, owing to a sharp increase in research
Q4 Earnings Preview: All eyes on Neutrolin trial updates from CorMedix
Biopharma firm CorMedix (NYSE American: CRMD) has seen its shares skyrocket more than 500% in the last 12 months as investors are
Aurora Cannabis appoints activist billionaire investor Nelson Peltz as strategic advisor
Aurora Cannabis (ACB) stock surged more than 10% in the pre-market trading as the company appointed activist investor Nelson Peltz as its